Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, Dény P. Eighth major clade for hepatitis delta virus. Emerg Infect Dis 2006;12:1447-50. [PMID: 17073101 PMCID: PMC3294742 DOI: 10.3201/eid1209.060112] [Citation(s) in RCA: 153] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open

For:	Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, Dény P. Eighth major clade for hepatitis delta virus. Emerg Infect Dis 2006;12:1447-50. [PMID: 17073101 PMCID: PMC3294742 DOI: 10.3201/eid1209.060112] [Citation(s) in RCA: 153] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open

Number

Cited by Other Article(s)

Wedemeyer H, Leus M, Battersby TR, Glenn J, Gordien E, Kamili S, Kapoor H, Kessler HH, Lenz O, Lütgehetmann M, Mixson-Hayden T, Simon CO, Thomson M, Westman G, Miller V, Terrault N, Lampertico P. HDV RNA assays: Performance characteristics, clinical utility, and challenges. Hepatology 2025;81:637-650. [PMID: 37640384 PMCID: PMC11289715 DOI: 10.1097/hep.0000000000000584] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Accepted: 06/15/2023] [Indexed: 08/31/2023]

Affiliation(s)

Heiner Wedemeyer Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany Excellence Cluster RESIST, Hannover Medical School, Hannover, Germany D-SOLVE: EU-funded Network on Individualized Management of Hepatitis D German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Braunschweig, Germany
Mitchell Leus Forum for Collaborative Research, School of Public Health, University of California, Berkeley, Washington DC Campus, Washington, District of Columbia, USA
Thomas R. Battersby Biomarker-IVD, Gilead Sciences, Inc., Foster City, California, USA
Jeffrey Glenn Departments of Medicine (Division of Gastroenterology and Hepatology) and Microbiology & Immunology, Stanford University School of Medicine, Stanford, California, USA
Emmanuel Gordien Laboratoire de microbiologie clinique, Centre National de Référence pour les virus des hépatites B, C et Delta, Hôpital Avicenne Assistance Publique – Hôpitaux de Paris, Bobigny, France
Saleem Kamili Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Hema Kapoor Ex Quest Diagnostics, HK Healthcare Consultant LLC, Secaucus, New Jersey, USA
Harald H. Kessler Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria
Oliver Lenz Clinical Microbiology and Immunology, Janssen Pharmaceutica NV, Beerse, Belgium
Marc Lütgehetmann Institute for Microbiology, Virology and Hygiene, University Medical Center Hamburg Eppendorf (UKE), Hamburg, Germany German Center for Infection Research (DZIF), Partner Site Hamburg, Lübeck, Kiel, Germany
Tonya Mixson-Hayden Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Christian O. Simon Clinical Development and Medical Affairs, Roche Diagnostics Solutions, Rotkreuz, Switzerland
Michael Thomson Division of Antivirals, US Food and Drug Administration, Silver Spring, Maryland, USA
Gabriel Westman Swedish Medical Products Agency, Uppsala, Sweden Department of Medical Sciences, Uppsala University, Uppsala, Sweden
Veronica Miller Forum for Collaborative Research, School of Public Health, University of California, Berkeley, Washington DC Campus, Washington, District of Columbia, USA
Norah Terrault Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
Pietro Lampertico Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy Department of Pathophysiology and Transplantation, CRC “A. M. and A. Migliavacca” Center for Liver Disease, University of Milan, Milan, Italy

Collapse

Angelice GP, Barros TM, Marques VA, Villar LM, Lago BV, Mello FCA. Exploring genetic diversity of hepatitis D virus full-length genome in Brazil: Discovery of a novel HDV-8 subgenotype beyond African borders. INFECTION, GENETICS AND EVOLUTION : JOURNAL OF MOLECULAR EPIDEMIOLOGY AND EVOLUTIONARY GENETICS IN INFECTIOUS DISEASES 2024;125:105671. [PMID: 39299539 DOI: 10.1016/j.meegid.2024.105671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/11/2024] [Revised: 09/13/2024] [Accepted: 09/16/2024] [Indexed: 09/22/2024]

Abstract

Hepatitis D virus (HDV) is currently classified into 8 genotypes (1 to 8) and several subgenotypes, with distinct distribution worldwide. However, due to the scarcity of complete genome sequences in databases, this classification is constantly being updated and tends to be regularly revisited in upcoming years as more sequence data becomes available. Aiming to increase knowledge about the genetic variability of HDV, this study presents the full-length genomes of 11 HDV samples collected in Brazil in endemic and non-endemic regions, including the first complete genomes of the genotypes 5 and 8 obtained outside Africa. We also determined the co-infecting HBV genotypes to investigate their prevalence among the HDV-infected individuals throughout the country. Whole genome sequencing confirmed our previous findings based on a partial fragment of the HDV genome, in which HDV subgenoypes 3c (9/11; 81.8 %), 5b (1/11; 9.1 %) and one HDV-8 sequence (1/11; 9.1 %) were detected. As previously observed, HDV-8 formed a distinct branch apart from subgenotypes 8a and 8b, a monophyletic clade representing a novel HDV-8 subgenotype, designated as 8c. Among HDV-3 samples, the main co-infecting HBV genotype found was HBV-F (4/8; 50 %), reflecting the higher incidence of this native South American genotype in the endemic Amazon Basin. Both samples infected with HDV-5 and HDV-8 were coinfected with HBV genotype E, also a genotype with African origin. Our findings based on complete genome sequence of HDV corroborated our results based on a partial region of the HDV genome of a novel HDV-8 subgenotype and reinforced the need to use full-length genomes to properly subdivide genotypes with very low intragroup genetic variability, such as HDV-3. The provision of these complete genomes is expected to contribute to the enrichment of sequence databases for future molecular and evolutionary investigations of HDV.

Collapse

Baruti K, Choga WT, Motshosi PC, Phinius BB, Phakedi B, Bhebhe LN, Mpebe GGA, Tsayang CD, Ratsoma T, Gaolathe T, Mosepele M, Makhema J, Shapiro R, Lockman S, Moyo S, Jongman M, Anderson M, Gaseitsiwe S. Hepatitis Delta Virus Clade 8 Is the Predominant Clade Circulating in Botswana amongst People Living with HIV. Viruses 2024;16:1568. [PMID: 39459902 PMCID: PMC11512356 DOI: 10.3390/v16101568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2024] [Revised: 09/27/2024] [Accepted: 10/01/2024] [Indexed: 10/28/2024] Open

Affiliation(s)

Kabo Baruti Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone Private Bag 00704, Botswana
Wonderful T. Choga Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone Private Bag 00704, Botswana
Patience C. Motshosi Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone Private Bag 00704, Botswana
Bonolo B. Phinius Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone Private Bag 00704, Botswana
Basetsana Phakedi Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone Private Bag 00704, Botswana
Lynnette N. Bhebhe Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.)
Gorata G. A. Mpebe Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.)
Chanana D. Tsayang Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.)
Tsholofelo Ratsoma Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone Private Bag 00704, Botswana
Tendani Gaolathe Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) Faculty of Medicine, University of Botswana, Gaborone Private Bag UB 0022, Botswana
Mosepele Mosepele Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) Faculty of Medicine, University of Botswana, Gaborone Private Bag UB 0022, Botswana
Joseph Makhema Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
Roger Shapiro Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
Shahin Lockman Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
Sikhulile Moyo Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA Department of Pathology, Division of Medical Virology, Stellenbosch University, Cape Town 7535, South Africa School of Health Systems and Public Health, University of Pretoria, Pretoria 0002, South Africa
Mosimanegape Jongman Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone Private Bag 00704, Botswana
Motswedi Anderson Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) Africa Health Research Institute (AHRI), Durban 4013, South Africa The Francis Crick Institute, London NW1 2BE, UK
Simani Gaseitsiwe Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana; (K.B.); (W.T.C.); (P.C.M.); (B.P.); (L.N.B.); (G.G.A.M.); (C.D.T.); (T.R.); (T.G.); (M.M.); (J.M.); (R.S.); (S.L.); (S.M.); (M.J.); (M.A.) Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Collapse

Quirino A, Marascio N, Branda F, Ciccozzi A, Romano C, Locci C, Azzena I, Pascale N, Pavia G, Matera G, Casu M, Sanna D, Giovanetti M, Ceccarelli G, Alaimo di Loro P, Ciccozzi M, Scarpa F, Maruotti A. Viral Hepatitis: Host Immune Interaction, Pathogenesis and New Therapeutic Strategies. Pathogens 2024;13:766. [PMID: 39338957 PMCID: PMC11435051 DOI: 10.3390/pathogens13090766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2024] [Revised: 08/30/2024] [Accepted: 09/02/2024] [Indexed: 09/30/2024] Open

Affiliation(s)

Angela Quirino Unit of Clinical Microbiology, Department of Health Sciences, “Magna Græcia” University of Catanzaro “Renato Dulbecco” Teaching Hospital, 88100 Catanzaro, Italy; (A.Q.); (N.M.); (G.P.); (G.M.)
Nadia Marascio Unit of Clinical Microbiology, Department of Health Sciences, “Magna Græcia” University of Catanzaro “Renato Dulbecco” Teaching Hospital, 88100 Catanzaro, Italy; (A.Q.); (N.M.); (G.P.); (G.M.)
Francesco Branda Unit of Medical Statistics and Molecular Epidemiology, Università Campus Bio-Medico di Roma, 00128 Rome, Italy; (C.R.); (M.C.)
Alessandra Ciccozzi Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy; (A.C.); (C.L.); (D.S.); (F.S.)
Chiara Romano Unit of Medical Statistics and Molecular Epidemiology, Università Campus Bio-Medico di Roma, 00128 Rome, Italy; (C.R.); (M.C.)
Chiara Locci Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy; (A.C.); (C.L.); (D.S.); (F.S.) Department of Veterinary Medicine, University of Sassari, 07100 Sassari, Italy; (I.A.); (N.P.); (M.C.)
Ilenia Azzena Department of Veterinary Medicine, University of Sassari, 07100 Sassari, Italy; (I.A.); (N.P.); (M.C.)
Noemi Pascale Department of Veterinary Medicine, University of Sassari, 07100 Sassari, Italy; (I.A.); (N.P.); (M.C.) Department of Chemical Physical Mathematical and Natural Sciences, University of Sassari, 07100 Sassari, Italy
Grazia Pavia Unit of Clinical Microbiology, Department of Health Sciences, “Magna Græcia” University of Catanzaro “Renato Dulbecco” Teaching Hospital, 88100 Catanzaro, Italy; (A.Q.); (N.M.); (G.P.); (G.M.)
Giovanni Matera Unit of Clinical Microbiology, Department of Health Sciences, “Magna Græcia” University of Catanzaro “Renato Dulbecco” Teaching Hospital, 88100 Catanzaro, Italy; (A.Q.); (N.M.); (G.P.); (G.M.)
Marco Casu Department of Veterinary Medicine, University of Sassari, 07100 Sassari, Italy; (I.A.); (N.P.); (M.C.)
Daria Sanna Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy; (A.C.); (C.L.); (D.S.); (F.S.)
Marta Giovanetti Department of Sciences and Technologies for Sustainable Development and One Health, Università Campus Bio-Medico di Roma, 00128 Rome, Italy; Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte 30190-002, MG, Brazil Climate Amplified Diseases and Epidemics (CLIMADE), Brasilia 70070-130, GO, Brazil
Giancarlo Ceccarelli Department of Public Health and Infectious Diseases, University Hospital Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy;
Pierfrancesco Alaimo di Loro Department GEPLI, Libera Università Maria Ss Assunta, 00193 Rome, Italy;
Massimo Ciccozzi Unit of Medical Statistics and Molecular Epidemiology, Università Campus Bio-Medico di Roma, 00128 Rome, Italy; (C.R.); (M.C.)
Fabio Scarpa Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy; (A.C.); (C.L.); (D.S.); (F.S.)
Antonello Maruotti Department GEPLI, Libera Università Maria Ss Assunta, 00193 Rome, Italy;

Collapse

Basimane-Bisimwa P, Koyaweda GW, Ngaïganam E, Vickos U, Sibiro OAD, Yambiyo BM, Sombié BS, Pélembi P, Moussa S, Bekondi C, Giles-Vernick T, Manirakiza A, Vray M, Komas NPJ. Seroprevalence and molecular characterization of viral hepatitis and HIV co-infection in the Central African Republic. PLoS One 2024;19:e0291155. [PMID: 38722944 PMCID: PMC11081248 DOI: 10.1371/journal.pone.0291155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Accepted: 04/19/2024] [Indexed: 05/13/2024] Open

Affiliation(s)

Parvine Basimane-Bisimwa Institut Pasteur de Bangui, Viral Hepatitis Laboratory, Bangui, Central African Republic Université Evangélique en Afrique (UEA), Bukavu, Democratic Republic of Congo International Center Advanced for Research and Training (ICART), Bukavu, Democratic Republic of Congo Hôpital Général de Référence de Panzi, Bukavu, Democratic Republic of Congo
Giscard Wilfried Koyaweda Institut Pasteur de Bangui, Viral Hepatitis Laboratory, Bangui, Central African Republic
Edgarthe Ngaïganam Institut Pasteur de Bangui, Viral Hepatitis Laboratory, Bangui, Central African Republic
Ulrich Vickos Laboratory of Arbovirus, Haemorrhagic Fevers, Institut Pasteur de Bangui, Emerging Virus and Zoonosis, Bangui, Central African Republic
Ornella Anne Demi Sibiro Institut Pasteur de Bangui, Viral Hepatitis Laboratory, Bangui, Central African Republic
Brice Martial Yambiyo Institut Pasteur de Bangui, Epidemiology Service, Bangui, Central African Republic
Benjamin Seydou Sombié Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
Pulchérie Pélembi Institut Pasteur de Bangui, Service des Retrovirus-VIH, Bangui, Central African Republic
Sandrine Moussa Institut Pasteur de Bangui, Service des Retrovirus-VIH, Bangui, Central African Republic
Claudine Bekondi Institut Pasteur de Bangui, Centre de Ressources Biologiques, Bangui, Central African Republic
Tamara Giles-Vernick Institut Pasteur-Université Paris Cité, Anthropology & Ecology of Disease Emergence Unit, INSERM, Paris, France
Alexandre Manirakiza Institut Pasteur de Bangui, Epidemiology Service, Bangui, Central African Republic
Muriel Vray Institut Pasteur-Université Paris Cité, Unit of Epidemiology of Emergent Infections, INSERM, Paris, France
Narcisse Patrice Joseph Komas Institut Pasteur de Bangui, Viral Hepatitis Laboratory, Bangui, Central African Republic

Collapse

Gopalakrishna H, Mironova M, Dahari H, Koh C, Heller T. Advances and Challenges in Managing Hepatitis D Virus: Evolving Strategies. CURRENT HEPATOLOGY REPORTS 2024;23:32-44. [PMID: 38533303 PMCID: PMC10965034 DOI: 10.1007/s11901-024-00643-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Accepted: 01/14/2024] [Indexed: 03/28/2024]

d'Arminio Monforte A, Tavelli A, Salpini R, Piermatteo L, D'Anna S, Carrara S, Malagnino V, Mazzotta V, Brancaccio G, Marchetti GC, Rosselli Del Turco E, Rossotti R, Mussini C, Antinori A, Lo Caputo S, Ceccherini Silberstein F, Gaeta GB, Svicher V, Puoti M. Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort. Liver Int 2024;44:603-613. [PMID: 38100128 DOI: 10.1111/liv.15804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Revised: 10/30/2023] [Accepted: 11/12/2023] [Indexed: 12/20/2023]

Affiliation(s)

Antonella d'Arminio Monforte ICONA Foundation, Milan, Italy
Alessandro Tavelli ICONA Foundation, Milan, Italy
Romina Salpini Department of Biology, University of Rome Tor Vergata, Rome, Italy
Lorenzo Piermatteo Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
Stefano D'Anna Department of Biology, University of Rome Tor Vergata, Rome, Italy
Stefania Carrara Unity of Microbiology and Biobank, INMI, Rome, Italy
Vincenzo Malagnino Department of Medicine of Systems, University of Rome Tor Vergata, Rome, Italy
Valentina Mazzotta Clinical and Research Infectious Diseases Department, INMI, Rome, Italy
Giuseppina Brancaccio Infectious Diseases, Department of Molecular Medicine, University of Padua, Padua, Italy
Giulia Carla Marchetti Department of Health Sciences, ASST Santi Paolo e Carlo, Clinic of Infectious Diseases, University of Milan, Milan, Italy
Elena Rosselli Del Turco Department of Medical and Surgical Sciences, Alma Mater Studiorum Bologna University, Bologna, Italy
Roberto Rossotti Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Ca' Granda Hospital, Milan, Italy
Cristina Mussini Clinic of Infectious Diseases, University Hospital of Modena, University of Modena and Reggio Emilia, Modena, Italy
Andrea Antinori Clinical and Research Infectious Diseases Department, INMI, Rome, Italy
Sergio Lo Caputo Clinic of Infectious Diseases, University of Foggia, Foggia, Italy
Francesca Ceccherini Silberstein Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
Giovanni Battista Gaeta University L. Vanvitelli, Infectious Diseases Unit, Naples, Italy
Valentina Svicher Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
Massimo Puoti Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Ca' Granda Hospital, Milan, Italy

Collapse

Dong J, Ismail N, Fitts E, Walker DH. Molecular testing in emerging infectious diseases. DIAGNOSTIC MOLECULAR PATHOLOGY 2024:175-198. [DOI: 10.1016/b978-0-12-822824-1.00011-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2025]

Ananchuensook P, Suksawatamnuay S, Thaimai P, Siripon N, Sriphoosanaphan S, Thanapirom K, Poovorawan Y, Komolmit P. Prevalence of hepatitis D virus infection among patients with chronic hepatitis B infection in a tertiary care centre in Thailand. Sci Rep 2023;13:22633. [PMID: 38114689 PMCID: PMC10730816 DOI: 10.1038/s41598-023-49819-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 12/12/2023] [Indexed: 12/21/2023] Open

Affiliation(s)

Prooksa Ananchuensook Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama4 Road, Patumwan, Bangkok, 10330, Thailand Center of Excellence in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand Center of Excellence in Hepatic Fibrosis and Cirrhosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Academic Affair, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Sirinporn Suksawatamnuay Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama4 Road, Patumwan, Bangkok, 10330, Thailand Center of Excellence in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand Center of Excellence in Hepatic Fibrosis and Cirrhosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Panarat Thaimai Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama4 Road, Patumwan, Bangkok, 10330, Thailand Center of Excellence in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand Center of Excellence in Hepatic Fibrosis and Cirrhosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Nipaporn Siripon Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama4 Road, Patumwan, Bangkok, 10330, Thailand Center of Excellence in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
Supachaya Sriphoosanaphan Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama4 Road, Patumwan, Bangkok, 10330, Thailand Center of Excellence in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand Center of Excellence in Hepatic Fibrosis and Cirrhosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Kessarin Thanapirom Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama4 Road, Patumwan, Bangkok, 10330, Thailand Center of Excellence in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand Center of Excellence in Hepatic Fibrosis and Cirrhosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Yong Poovorawan Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Piyawat Komolmit Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama4 Road, Patumwan, Bangkok, 10330, Thailand. Center of Excellence in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. Center of Excellence in Hepatic Fibrosis and Cirrhosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Collapse

Beghin J, Meier-Stephenson V. Does hepatitis delta virus have a preference for hepatitis B virus genotype? A systematic review of the literature. J Viral Hepat 2023;30:906-913. [PMID: 37786351 DOI: 10.1111/jvh.13889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 08/21/2023] [Accepted: 09/21/2023] [Indexed: 10/04/2023]

Tian Y, Fan Z, Zhang X, Xu L, Cao Y, Pan Z, Mo Y, Gao Y, Zheng S, Huang J, Zou H, Duan Z, Li H, Ren F. CRISPR/Cas13a-Assisted accurate and portable hepatitis D virus RNA detection. Emerg Microbes Infect 2023;12:2276337. [PMID: 37882492 PMCID: PMC10796118 DOI: 10.1080/22221751.2023.2276337] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Accepted: 10/23/2023] [Indexed: 10/27/2023]

Affiliation(s)

Yuan Tian Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Zihao Fan Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Xiangying Zhang Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Ling Xu Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Yaling Cao Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Zhenzhen Pan Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Yinkang Mo Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Yao Gao Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Sujun Zheng Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Jing Huang Department of Infection Control, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
Huaibin Zou Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Zhongping Duan Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Hao Li State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, People’s Republic of China
Feng Ren Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China

Collapse

Ferrante ND, Kallan MJ, Sukkestad S, Kodani M, Kitahata MM, Cachay ER, Bhattacharya D, Heath S, Napravnik S, Moore RD, Yendewa G, Mayer KH, Reddy KR, Hayden T, Kamili S, Martin JN, Kim HN, Lo Re V. Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B-coinfected adults in care in the United States. J Viral Hepat 2023;30:879-888. [PMID: 37488783 PMCID: PMC10592429 DOI: 10.1111/jvh.13874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 07/07/2023] [Indexed: 07/26/2023]

Affiliation(s)

Nicole D. Ferrante Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA
Michael J. Kallan Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Sophia Sukkestad Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA
Maja Kodani Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA
Mari M. Kitahata Division of Allergy and Infectious Disease, Department of Medicine, University of Washington School of Medicine, Seattle, WA
Edward R. Cachay Department of Medicine, Division of Infectious Diseases and Global Public Health University of California, San Diego, CA
Debika Bhattacharya Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA
Sonya Heath Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, AL
Sonia Napravnik Department of Medicine, University of North Carolina, Chapel Hill, NC
Richard D. Moore Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD
George Yendewa Department of Medicine, Case Western Reserve University, Cleveland, OH
Kenneth H. Mayer The Fenway Institute, Fenway Health, Boston, MA; Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
K. Rajender Reddy Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Tonya Hayden Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA
Saleem Kamili Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA
Jeffrey N. Martin Department of Epidemiology and Biostatistics, University of California, San Francisco, CA
H. Nina Kim Division of Allergy and Infectious Disease, Department of Medicine, University of Washington School of Medicine, Seattle, WA
Vincent Lo Re Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Collapse

Yen DW, Soriano V, Barreiro P, Sherman KE. Triple Threat: HDV, HBV, HIV Coinfection. Clin Liver Dis 2023;27:955-972. [PMID: 37778779 DOI: 10.1016/j.cld.2023.05.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/03/2023]

Salichos L, Minosse C, Visco-Comandini U, Taibi C, Zulian V, D’Offizi G, Pallothu N, McPhee F, Garbuglia AR. Phylogenetic and Phylodynamic Analysis of Delta Strains Circulating in Italy. Viruses 2023;15:1791. [PMID: 37766200 PMCID: PMC10537423 DOI: 10.3390/v15091791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 08/18/2023] [Accepted: 08/22/2023] [Indexed: 09/29/2023] Open

Soriano V, de Mendoza C, Treviño A, Ramos-Rincón JM, Moreno-Torres V, Corral O, Barreiro P. Treatment of hepatitis delta and HIV infection. Liver Int 2023;43 Suppl 1:108-115. [PMID: 35748639 DOI: 10.1111/liv.15345] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Accepted: 06/20/2022] [Indexed: 01/18/2023]

Heller T, Buti M, Lampertico P, Wedemeyer H. Hepatitis D: Looking Back, Looking Forward, Seeing the Reward and the Promise. Clin Gastroenterol Hepatol 2023;21:2051-2064. [DOI: 10.1016/j.cgh.2023.04.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2025]

Mello FCA, Barros TM, Angelice GP, Costa VD, Mello VM, Pardini MIMC, Lampe E, Lago BV, Villar LM. Circulation of HDV Genotypes in Brazil: Identification of a Putative Novel HDV-8 Subgenotype. Microbiol Spectr 2023;11:e0396522. [PMID: 37074189 PMCID: PMC10269522 DOI: 10.1128/spectrum.03965-22] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Accepted: 03/09/2023] [Indexed: 04/20/2023] Open

Abstract

Hepatitis D virus (HDV) is classified into 8 genotypes (1 to 8) and several subgenotypes. In Brazil, HDV-3 and HDV-1 predominate; however, most of the diagnosis efforts and molecular studies are directed to the area of endemicity of the Amazon Basin. Here, we determined the molecular epidemiological profile of circulating HDV in Brazilian HBsAg-positive patients between 2013 and 2015 in areas of endemicity and non-areas of endemicity. From 38 anti-HDV-positive individuals, 13 (34.2%) had detectable HDV-RNA and 11 (28.9%) were successfully sequenced. Partial HDAg (~320 nt) sequencing followed by phylogenetic analysis with reference sequences resulted in the identification of HDV-3 (9/11; 81.8%), HDV-5 (1/11; 9.1%), and HDV-8 (1/11; 9.1%). Most HDV-3 samples (8/9; 88.9%) were found in the endemic North region, while one was found in Central-West Brazil, a non-area of endemicity. HDV-5 and 8, genotypes native from African countries, were found in São Paulo, a cosmopolitan city from Southeast Brazil with a high circulation of immigrants. Phylogenetic analysis of HDV-8 strains indicated that the sample determined in our study, along with previously reported sequences from Brazil, formed a highly supported monophyletic clade, likely representing a putative novel HDV-8 subgenotype. IMPORTANCE Considered a neglected pathogen until the last 2 decades, an increase in the availability of genetic data of hepatitis D virus (HDV) strains around the world has been noticed recently, resulting in the proposition of different classifications. Our study aimed to determine the molecular epidemiological profile of HDV isolates circulating in areas of endemicity and non-areas of endemicity in Brazil. Based on the analyzed fragment, HDV-8 sequences clustered out of the clades formed by subgenotypes 8a and 8b might suggest the identification of a novel subgenotype, putatively designated subgenotype 8c. Our findings demonstrate the importance of continuous epidemiological surveillance to map HDV spread pathways and the introduction of imported variants. It also reinforces that as the amount of HDV genomes generated and reported increases, we will have changes in viral classification and, consequently, in our understanding of the dynamics of variability of this viral agent.

Collapse

Hermanussen L, Lampalzer S, Bockmann JH, Ziegler AE, Piecha F, Dandri M, Pischke S, Haag F, Lohse AW, Lütgehetmann M, Weiler-Normann C, zur Wiesch JS. Non-organ-specific autoantibodies with unspecific patterns are a frequent para-infectious feature of chronic hepatitis D. Front Med (Lausanne) 2023;10:1169096. [PMID: 37387781 PMCID: PMC10300640 DOI: 10.3389/fmed.2023.1169096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2023] [Accepted: 05/18/2023] [Indexed: 07/01/2023] Open

Affiliation(s)

Lennart Hermanussen Department of Medicine (Gastroenterology, Hepatology, Infectious diseases, and Tropical Medicine), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
Sibylle Lampalzer Department of Medicine (Gastroenterology, Hepatology, Infectious diseases, and Tropical Medicine), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
Jan-Hendrik Bockmann Department of Medicine (Gastroenterology, Hepatology, Infectious diseases, and Tropical Medicine), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, Hamburg, Germany
Annerose E. Ziegler Department of Medicine (Gastroenterology, Hepatology, Infectious diseases, and Tropical Medicine), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
Felix Piecha Department of Medicine (Gastroenterology, Hepatology, Infectious diseases, and Tropical Medicine), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, Hamburg, Germany
Maura Dandri Department of Medicine (Gastroenterology, Hepatology, Infectious diseases, and Tropical Medicine), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, Hamburg, Germany
Sven Pischke Department of Medicine (Gastroenterology, Hepatology, Infectious diseases, and Tropical Medicine), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, Hamburg, Germany
Friedrich Haag Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Ansgar W. Lohse Department of Medicine (Gastroenterology, Hepatology, Infectious diseases, and Tropical Medicine), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, Hamburg, Germany
Marc Lütgehetmann German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, Hamburg, Germany Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
Christina Weiler-Normann Department of Medicine (Gastroenterology, Hepatology, Infectious diseases, and Tropical Medicine), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany Department of Medicine and Martin Zeitz Centre for Rare Diseases, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
Julian Schulze zur Wiesch Department of Medicine (Gastroenterology, Hepatology, Infectious diseases, and Tropical Medicine), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Site, Hamburg, Germany Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Collapse

Mangia A, Squillante MM, Fraticelli F, Cavorsi MC, Paroni G, Zaffarano L, Piazzolla AV. HDV RNA Levels and Progression of Hepatitis Delta Infection: A 14 Year Follow Up Experience in Italy. Cells 2023;12:1413. [PMID: 37408247 DOI: 10.3390/cells12101413] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 05/12/2023] [Accepted: 05/15/2023] [Indexed: 07/07/2023] Open

Abstract

BACKGROUND

Identification of outcome predictors is one of the unmet needs in chronic HDV infection. Until recently, no reliable quantitative assays for HDV RNA were available.

AIMS

To evaluate the impact of baseline viremia on natural history of HDV infection in a cohort of patients whose serum samples were stored at their first visit 15 years ago.

METHODS

Quantitative HBsAg, HBeAg, HBeAb, HBV DNA, HDV RNA, genotypes, and liver disease severity were assessed at baseline. Patients who were no longer on active follow-up were recalled and re-evaluated in August 2022.

RESULTS

The majority of patients were male (64.9%); the median age was 50.1 years; and all patients were Italian, with only three born in Romania. All were HBeAg negative with HBV genotype D infection. Patients were subdivided three groups: 23 were in active follow-up (Group 1), 21 were recalled due to no longer being in follow-up (Group 2), and 11 died (Group 3). Liver cirrhosis was diagnosed in 28 subjects at the first visit; 39.3% of diagnosed patients were in Group 3, 32.1% were in Group 1 and 28.6% were in Group 2 (p = 0.001). Baseline HBV DNA IU/mL Log10 were 1.6 (1.0-5.9) in Group 1, 1.3 (1.0-4.5) in Group 2, and 4.1 (1.5-4.5) in Group 3; median baseline HDV RNA Log10 levels were 4.1 (0.7-6.7) in Group 1, 3.2 (0.7-6.2) in Group 2, and 5.2 (0.7-6.7) in Group 3, resulting significantly higher rates among patients in Group 3 compared to the other groups (p = 0.038). Eighteen patients in Group 2, as compared to 7 in Group 1, had undetectable HDV RNA at the follow-up evaluation (p = 0.001).

CONCLUSIONS

HDV chronic infection is a heterogeneous disease. It may not only progress but also improve over time in patients, who eventually become HDV RNA-undetectable. HDV RNA levels may help identify the subgroup of patients with less progressive liver disease.

Collapse

Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment. JHEP Rep 2023;5:100673. [PMID: 36908749 PMCID: PMC9996322 DOI: 10.1016/j.jhepr.2023.100673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 12/02/2022] [Accepted: 01/03/2023] [Indexed: 01/25/2023] Open

Abstract

Background & Aims

Pegylated interferon alpha (pegIFNα) is commonly used for the treatment of people infected with HDV. However, its mode of action in HDV-infected cells remains elusive and only a minority of people respond to pegIFNα therapy. Herein, we aimed to assess the responsiveness of three different cloned HDV strains to pegIFNα. We used a previously cloned HDV genotype 1 strain (dubbed HDV-1a) that appeared insensitive to interferon-α in vitro, a new HDV strain (HDV-1p) we isolated from an individual achieving later sustained response to IFNα therapy, and one phylogenetically distant genotype 3 strain (HDV-3).

Methods

PegIFNα was administered to human liver chimeric mice infected with HBV and the different HDV strains or to HBV/HDV infected human hepatocytes isolated from chimeric mice. Virological parameters and host responses were analysed by qPCR, sequencing, immunoblotting, RNA in situ hybridisation and immunofluorescence staining.

Results

PegIFNα treatment efficiently reduced HDV RNA viraemia (∼2-log) and intrahepatic HDV markers both in mice infected with HBV/HDV-1p and HBV/HDV-3. In contrast, HDV parameters remained unaffected by pegIFNα treatment both in mice (up to 9 weeks) and in isolated cells infected with HBV/HDV-1a. Notably, HBV viraemia was efficiently lowered (∼2-log) and human interferon-stimulated genes similarly induced in all three HBV/HDV-infected mouse groups receiving pegIFNα. Genome sequencing revealed highly conserved ribozyme and L-hepatitis D antigen post-translational modification sites among all three isolates.

Conclusions

Our comparative study indicates the ability of pegIFNα to lower HDV loads in stably infected human hepatocytes in vivo and the existence of complex virus-specific determinants of IFNα responsiveness.

Impact and implications

Understanding factors counteracting HDV infections is paramount to develop curative therapies. We compared the responsiveness of three different cloned HDV strains to pegylated interferon alpha in chronically infected mice. The different responsiveness of these HDV isolates to treatment highlights a previously underestimated heterogeneity among HDV strains.

Collapse

Tassachew Y, Belyhun Y, Abebe T, Mihret A, Teffera T, Ababi G, Shewaye A, Desalegn H, Aseffa A, Mulu A, Howe R, Liebert UG, Maier M. Magnitude and genotype of hepatitis delta virus among chronic hepatitis B carriers with a spectrum of liver diseases in Ethiopia. Ann Hepatol 2023;28:100770. [PMID: 36220615 DOI: 10.1016/j.aohep.2022.100770] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 09/23/2022] [Accepted: 09/28/2022] [Indexed: 02/04/2023]

Affiliation(s)

Yayehyirad Tassachew Department of Microbiology, Immunology, and Parasitology, School of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; Institute of Virology, University of Leipzig, 04103 Leipzig, Germany; Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia; School of Medicine, College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia.
Yeshambel Belyhun Institute of Virology, University of Leipzig, 04103 Leipzig, Germany; School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
Tamrat Abebe Department of Microbiology, Immunology, and Parasitology, School of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
Adane Mihret Department of Microbiology, Immunology, and Parasitology, School of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia
Tezazu Teffera School of Medicine, College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia
Girma Ababi School of Medicine, College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia; Yanet Specialized Clinic, Hawassa, Ethiopia
Abate Shewaye Department of Internal Medicine, School of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; Adera Medical Center PLC, Addis Ababa, Ethiopia
Hailemichael Desalegn Department of Internal Medicine, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia
Abraham Aseffa Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia
Andargachew Mulu Institute of Virology, University of Leipzig, 04103 Leipzig, Germany; Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia
Rawleigh Howe Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia
Uwe G Liebert Institute of Virology, University of Leipzig, 04103 Leipzig, Germany
Melanie Maier Institute of Virology, University of Leipzig, 04103 Leipzig, Germany

Collapse

Khalfi P, Kennedy PT, Majzoub K, Asselah T. Hepatitis D virus: Improving virological knowledge to develop new treatments. Antiviral Res 2023;209:105461. [PMID: 36396025 DOI: 10.1016/j.antiviral.2022.105461] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 10/21/2022] [Accepted: 11/05/2022] [Indexed: 11/16/2022]

Lange M, Zaret D, Kushner T. Hepatitis Delta: Current Knowledge and Future Directions. Gastroenterol Hepatol (N Y) 2022;18:508-520. [PMID: 36397990 PMCID: PMC9666792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]

Bahoussi AN, Wang PH, Guo YY, Rabbani N, Wu C, Xing L. Global Distribution and Natural Recombination of Hepatitis D Virus: Implication of Kyrgyzstan Emerging HDVs in the Clinical Outcomes. Viruses 2022;14:v14071467. [PMID: 35891448 PMCID: PMC9323457 DOI: 10.3390/v14071467] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Revised: 06/28/2022] [Accepted: 06/30/2022] [Indexed: 02/05/2023] Open

Usai C, Gill US, Riddell AC, Asselah T, Kennedy P. Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus. Aliment Pharmacol Ther 2022;55:978-993. [PMID: 35292991 PMCID: PMC9314912 DOI: 10.1111/apt.16807] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 10/06/2021] [Accepted: 01/25/2022] [Indexed: 12/16/2022]

Hepatitis D: advances and challenges. Chin Med J (Engl) 2022;135:767-773. [PMID: 35234694 PMCID: PMC9276264 DOI: 10.1097/cm9.0000000000002011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open

Pacin-Ruiz B, Cortese MF, Tabernero D, Sopena S, Gregori J, García-García S, Casillas R, Najarro A, Aldama U, Palom A, Rando-Segura A, Galán A, Vila M, Riveiro-Barciela M, Quer J, González-Aseguinolaza G, Buti M, Rodríguez-Frías F. Inspecting the Ribozyme Region of Hepatitis Delta Virus Genotype 1: Conservation and Variability. Viruses 2022;14:v14020215. [PMID: 35215809 PMCID: PMC8877431 DOI: 10.3390/v14020215] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 01/18/2022] [Accepted: 01/19/2022] [Indexed: 02/07/2023] Open

Affiliation(s)

Beatriz Pacin-Ruiz Liver Pathology Unit, Departments of Biochemistry and Microbiology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (B.P.-R.); (S.S.); (S.G.-G.); (R.C.); (A.N.); (U.A.); (A.G.); (M.V.); (F.R.-F.) Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, 28029 Madrid, Spain; (M.R.-B.); (M.B.)
María Francesca Cortese Liver Pathology Unit, Departments of Biochemistry and Microbiology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (B.P.-R.); (S.S.); (S.G.-G.); (R.C.); (A.N.); (U.A.); (A.G.); (M.V.); (F.R.-F.) Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, 28029 Madrid, Spain; (M.R.-B.); (M.B.) Correspondence: (M.F.C.); (D.T.)
David Tabernero Liver Pathology Unit, Departments of Biochemistry and Microbiology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (B.P.-R.); (S.S.); (S.G.-G.); (R.C.); (A.N.); (U.A.); (A.G.); (M.V.); (F.R.-F.) Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, 28029 Madrid, Spain; (M.R.-B.); (M.B.) Correspondence: (M.F.C.); (D.T.)
Sara Sopena Liver Pathology Unit, Departments of Biochemistry and Microbiology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (B.P.-R.); (S.S.); (S.G.-G.); (R.C.); (A.N.); (U.A.); (A.G.); (M.V.); (F.R.-F.)
Josep Gregori Liver Unit, Liver Disease, Laboratory-Viral Hepatitis, Vall d’Hebron Institut Recerca-Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (J.G.); (J.Q.)
Selene García-García Liver Pathology Unit, Departments of Biochemistry and Microbiology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (B.P.-R.); (S.S.); (S.G.-G.); (R.C.); (A.N.); (U.A.); (A.G.); (M.V.); (F.R.-F.) Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, 28029 Madrid, Spain; (M.R.-B.); (M.B.)
Rosario Casillas Liver Pathology Unit, Departments of Biochemistry and Microbiology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (B.P.-R.); (S.S.); (S.G.-G.); (R.C.); (A.N.); (U.A.); (A.G.); (M.V.); (F.R.-F.)
Adrián Najarro Liver Pathology Unit, Departments of Biochemistry and Microbiology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (B.P.-R.); (S.S.); (S.G.-G.); (R.C.); (A.N.); (U.A.); (A.G.); (M.V.); (F.R.-F.)
Unai Aldama Liver Pathology Unit, Departments of Biochemistry and Microbiology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (B.P.-R.); (S.S.); (S.G.-G.); (R.C.); (A.N.); (U.A.); (A.G.); (M.V.); (F.R.-F.)
Adriana Palom Liver Unit, Department of Internal Medicine, Vall d’Hebron University Hospital, 08035 Barcelona, Spain;
Ariadna Rando-Segura Department of Microbiology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain;
Anna Galán Liver Pathology Unit, Departments of Biochemistry and Microbiology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (B.P.-R.); (S.S.); (S.G.-G.); (R.C.); (A.N.); (U.A.); (A.G.); (M.V.); (F.R.-F.)
Marta Vila Liver Pathology Unit, Departments of Biochemistry and Microbiology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (B.P.-R.); (S.S.); (S.G.-G.); (R.C.); (A.N.); (U.A.); (A.G.); (M.V.); (F.R.-F.)
Mar Riveiro-Barciela Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, 28029 Madrid, Spain; (M.R.-B.); (M.B.) Liver Unit, Department of Internal Medicine, Vall d’Hebron University Hospital, 08035 Barcelona, Spain;
Josep Quer Liver Unit, Liver Disease, Laboratory-Viral Hepatitis, Vall d’Hebron Institut Recerca-Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (J.G.); (J.Q.)
Gloria González-Aseguinolaza Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain;
María Buti Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, 28029 Madrid, Spain; (M.R.-B.); (M.B.) Liver Unit, Department of Internal Medicine, Vall d’Hebron University Hospital, 08035 Barcelona, Spain;
Francisco Rodríguez-Frías Liver Pathology Unit, Departments of Biochemistry and Microbiology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain; (B.P.-R.); (S.S.); (S.G.-G.); (R.C.); (A.N.); (U.A.); (A.G.); (M.V.); (F.R.-F.) Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, 28029 Madrid, Spain; (M.R.-B.); (M.B.) Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Plaça Cívica, 08193 Bellaterra, Spain

Collapse

Adaptive Immune Responses, Immune Escape and Immune-Mediated Pathogenesis during HDV Infection. Viruses 2022;14:v14020198. [PMID: 35215790 PMCID: PMC8880046 DOI: 10.3390/v14020198] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 01/14/2022] [Accepted: 01/16/2022] [Indexed: 12/13/2022] Open

Nagata S, Kiyohara R, Toh H. Constraint of Base Pairing on HDV Genome Evolution. Viruses 2021;13:v13122350. [PMID: 34960619 PMCID: PMC8708965 DOI: 10.3390/v13122350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 10/11/2021] [Accepted: 11/02/2021] [Indexed: 11/17/2022] Open

[Delta hepatitis: Epidemiology, diagnostic, natural history and treatment]. Rev Med Interne 2021;43:160-169. [PMID: 34799189 DOI: 10.1016/j.revmed.2021.10.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 09/17/2021] [Accepted: 10/17/2021] [Indexed: 11/20/2022]

Chen LY, Pang XY, Goyal H, Yang RX, Xu HG. Hepatitis D: challenges in the estimation of true prevalence and laboratory diagnosis. Gut Pathog 2021;13:66. [PMID: 34717740 PMCID: PMC8557527 DOI: 10.1186/s13099-021-00462-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 10/19/2021] [Indexed: 02/07/2023] Open

Hayashi T, Takeshita Y, Hutin YJF, Harmanci H, Easterbrook P, Hess S, van Holten J, Oru EO, Kaneko S, Yurdaydin C, Bulterys M. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response? Arch Public Health 2021;79:180. [PMID: 34663473 PMCID: PMC8525025 DOI: 10.1186/s13690-021-00693-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Accepted: 09/13/2021] [Indexed: 12/02/2022] Open

Giersch K, Hermanussen L, Volz T, Volmari A, Allweiss L, Sureau C, Casey J, Huang J, Fischer N, Lütgehetmann M, Dandri M. Strong Replication Interference Between Hepatitis Delta Viruses in Human Liver Chimeric Mice. Front Microbiol 2021;12:671466. [PMID: 34305837 PMCID: PMC8297590 DOI: 10.3389/fmicb.2021.671466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 06/08/2021] [Indexed: 11/13/2022] Open

Abstract

Background

Hepatitis D Virus (HDV) is classified into eight genotypes with distinct clinical outcomes. Despite the maintenance of highly conserved functional motifs, it is unknown whether sequence divergence between genotypes, such as HDV-1 and HDV-3, or viral interference mechanisms may affect co-infection in the same host and cell, thus hindering the development of HDV inter-genotypic recombinants. We aimed to investigate virological differences of HDV-1 and HDV-3 and assessed their capacity to infect and replicate within the same liver and human hepatocyte in vivo.

Methods

Human liver chimeric mice were infected with hepatitis B virus (HBV) and with one of the two HDV genotypes or with HDV-1 and HDV-3 simultaneously. In a second set of experiments, HBV-infected mice were first infected with HDV-1 and after 9 weeks with HDV-3, or vice versa. Also two distinct HDV-1 strains were used to infect mice simultaneously and sequentially. Virological parameters were determined by strain-specific qRT-PCR, RNA in situ hybridization and immunofluorescence staining.

Results

HBV/HDV co-infection studies indicated faster spreading kinetics and higher intrahepatic levels of HDV-3 compared to HDV-1. In mice that simultaneously received both HDV strains, HDV-3 became the dominant genotype. Interestingly, antigenomic HDV-1 and HDV-3 RNA were detected within the same liver but hardly within the same cell. Surprisingly, sequential super-infection experiments revealed a clear dominance of the HDV strain that was inoculated first, indicating that HDV-infected cells may acquire resistance to super-infection.

Conclusion

Infection with two largely divergent HDV genotypes could be established in the same liver, but rarely within the same hepatocyte. Sequential super-infection with distinct HDV genotypes and even with two HDV-1 isolates was strongly impaired, suggesting that virus interference mechanisms hamper productive replication in the same cell and hence recombination events even in a system lacking adaptive immune responses.

Collapse

HDV Pathogenesis: Unravelling Ariadne's Thread. Viruses 2021;13:v13050778. [PMID: 33924806 PMCID: PMC8145675 DOI: 10.3390/v13050778] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 04/22/2021] [Accepted: 04/23/2021] [Indexed: 12/22/2022] Open

In Vivo Models of HDV Infection: Is Humanizing NTCP Enough? Viruses 2021;13:v13040588. [PMID: 33807170 PMCID: PMC8065588 DOI: 10.3390/v13040588] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 03/26/2021] [Accepted: 03/28/2021] [Indexed: 12/28/2022] Open

Sagnelli C, Sagnelli E, Russo A, Pisaturo M, Occhiello L, Coppola N. HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges. Life (Basel) 2021;11:life11020169. [PMID: 33671730 PMCID: PMC7926847 DOI: 10.3390/life11020169] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 02/18/2021] [Accepted: 02/18/2021] [Indexed: 02/06/2023] Open

Hoan NX, Hoechel M, Tomazatos A, Anh CX, Pallerla SR, Linh LTK, Binh MT, Sy BT, Toan NL, Wedemeyer H, Bock CT, Kremsner PG, Meyer CG, Song LH, Velavan TP. Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis. Viruses 2021;13:v13020346. [PMID: 33671832 PMCID: PMC7926858 DOI: 10.3390/v13020346] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 02/04/2021] [Accepted: 02/18/2021] [Indexed: 12/15/2022] Open

Affiliation(s)

Nghiem Xuan Hoan Institute of Tropical Medicine, University of Tübingen, 72076 Tübingen, Germany; (N.X.H.); (M.H.); (A.T.); (S.R.P.); (L.T.K.L.); (M.T.B.); (P.G.K.); (C.G.M.) Vietnamese-German Center for Medical Research, VG-CARE, Hanoi, Vietnam; (C.X.A.); (B.T.S.); (L.H.S.) Institute of Clinical Infectious Diseases, 108 Military Central Hospital, Hanoi, Vietnam
Mirjam Hoechel Institute of Tropical Medicine, University of Tübingen, 72076 Tübingen, Germany; (N.X.H.); (M.H.); (A.T.); (S.R.P.); (L.T.K.L.); (M.T.B.); (P.G.K.); (C.G.M.)
Alexandru Tomazatos Institute of Tropical Medicine, University of Tübingen, 72076 Tübingen, Germany; (N.X.H.); (M.H.); (A.T.); (S.R.P.); (L.T.K.L.); (M.T.B.); (P.G.K.); (C.G.M.)
Chu Xuan Anh Vietnamese-German Center for Medical Research, VG-CARE, Hanoi, Vietnam; (C.X.A.); (B.T.S.); (L.H.S.) Institute of Clinical Infectious Diseases, 108 Military Central Hospital, Hanoi, Vietnam
Srinivas Reddy Pallerla Institute of Tropical Medicine, University of Tübingen, 72076 Tübingen, Germany; (N.X.H.); (M.H.); (A.T.); (S.R.P.); (L.T.K.L.); (M.T.B.); (P.G.K.); (C.G.M.)
Le Thi Kieu Linh Institute of Tropical Medicine, University of Tübingen, 72076 Tübingen, Germany; (N.X.H.); (M.H.); (A.T.); (S.R.P.); (L.T.K.L.); (M.T.B.); (P.G.K.); (C.G.M.) Vietnamese-German Center for Medical Research, VG-CARE, Hanoi, Vietnam; (C.X.A.); (B.T.S.); (L.H.S.)
Mai Thanh Binh Institute of Tropical Medicine, University of Tübingen, 72076 Tübingen, Germany; (N.X.H.); (M.H.); (A.T.); (S.R.P.); (L.T.K.L.); (M.T.B.); (P.G.K.); (C.G.M.) Vietnamese-German Center for Medical Research, VG-CARE, Hanoi, Vietnam; (C.X.A.); (B.T.S.); (L.H.S.) Institute of Clinical Infectious Diseases, 108 Military Central Hospital, Hanoi, Vietnam
Bui Tien Sy Vietnamese-German Center for Medical Research, VG-CARE, Hanoi, Vietnam; (C.X.A.); (B.T.S.); (L.H.S.) Institute of Clinical Infectious Diseases, 108 Military Central Hospital, Hanoi, Vietnam
Nguyen Linh Toan Department of Pathophysiology, Vietnam Military Medical University, Hanoi, Vietnam;
Heiner Wedemeyer Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30623 Hannover, Germany;
C.-Thomas Bock Department of Infectious Diseases, Robert Koch Institute, 13353 Berlin, Germany;
Peter G. Kremsner Institute of Tropical Medicine, University of Tübingen, 72076 Tübingen, Germany; (N.X.H.); (M.H.); (A.T.); (S.R.P.); (L.T.K.L.); (M.T.B.); (P.G.K.); (C.G.M.) Centre de Recherches Medicales de Lambarene, Lambaréné, Gabon
Christian G. Meyer Institute of Tropical Medicine, University of Tübingen, 72076 Tübingen, Germany; (N.X.H.); (M.H.); (A.T.); (S.R.P.); (L.T.K.L.); (M.T.B.); (P.G.K.); (C.G.M.) Vietnamese-German Center for Medical Research, VG-CARE, Hanoi, Vietnam; (C.X.A.); (B.T.S.); (L.H.S.)
Le Huu Song Vietnamese-German Center for Medical Research, VG-CARE, Hanoi, Vietnam; (C.X.A.); (B.T.S.); (L.H.S.) Institute of Clinical Infectious Diseases, 108 Military Central Hospital, Hanoi, Vietnam
Thirumalaisamy P. Velavan Institute of Tropical Medicine, University of Tübingen, 72076 Tübingen, Germany; (N.X.H.); (M.H.); (A.T.); (S.R.P.); (L.T.K.L.); (M.T.B.); (P.G.K.); (C.G.M.) Vietnamese-German Center for Medical Research, VG-CARE, Hanoi, Vietnam; (C.X.A.); (B.T.S.); (L.H.S.) Correspondence: ; Tel.: +49-7071-2985981

Collapse

Giersch K, Hermanussen L, Volz T, Kah J, Allweiss L, Casey J, Sureau C, Dandri M, Lütgehetmann M. Murine hepatocytes do not support persistence of Hepatitis D virus mono-infection in vivo. Liver Int 2021;41:410-419. [PMID: 32997847 DOI: 10.1111/liv.14677] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Revised: 09/17/2020] [Accepted: 09/18/2020] [Indexed: 12/12/2022]

Roulot D, Brichler S, Layese R, BenAbdesselam Z, Zoulim F, Thibault V, Scholtes C, Roche B, Castelnau C, Poynard T, Chazouillères O, Ganne N, Fontaine H, Gournay J, Guyader D, Le Gal F, Nahon P, Roudot-Thoraval F, Gordien E, Landman R, Hezode C, Riachi G, Lascoux-Combe C, Loustaud-Ratti V, Rosa I, Mathurin P, Nguyen-Khac E, Causse X, Naveau S, Habersetzer F, Metivier S, Labadie H, Sellier P, Bottero J, de Ledinghen V, Alric L, Calès P, Goujard C, Cadranel JF, Salmon D, Hillaire S. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. J Hepatol 2020;73:1046-1062. [PMID: 32634548 DOI: 10.1016/j.jhep.2020.06.038] [Citation(s) in RCA: 101] [Impact Index Per Article: 20.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Revised: 06/04/2020] [Accepted: 06/23/2020] [Indexed: 02/07/2023]

Abstract

BACKGROUND & AIMS

HDV infection causes severe chronic liver disease in individuals infected with HBV. However, the factors associated with poor prognosis are largely unknown. Thus, we aimed to identify prognostic factors in patients with HDV infection.

METHODS

The French National Reference Centre for HDV performed a nationwide retrospective study on 1,112 HDV-infected patients, collecting epidemiological, clinical, virological and histological data from the initial referral to the last recorded follow-up.

RESULTS

The median age of our cohort was 36.5 (29.9-43.2) years and 68.6% of our cohort were male. Most patients whose birthplace was known were immigrants from sub-Saharan Africa (52.5%), southern and eastern Europe (21.3%), northern Africa and the Middle East (6.2%), Asia (5.9%) and South America (0.3%). Only 150 patients (13.8%) were French native. HDV load was positive in 659 of 748 tested patients (88.1%). HDV-1 was predominant (75.9%), followed by sub-Saharan genotypes: HDV-5 (17.6%), HDV-7 (2.9%), HDV-6 (1.8%) and HDV-8 (1.6%). At referral, 312 patients (28.2%) had cirrhosis, half having experienced at least 1 episode of hepatic decompensation. Cirrhosis was significantly less frequent in African than in European patients regardless of HDV genotype. At the end of follow-up (median 3.0 [0.8-7.2] years), 48.8% of the patients had developed cirrhosis, 24.2% had ≥1 episode(s) of decompensation and 9.2% had hepatocellular carcinoma. European HDV-1 and African HDV-5 patients were more at risk of developing cirrhosis. Persistent replicative HDV infection was associated with decompensation, hepatocellular carcinoma and death. African patients displayed better response to interferon therapy than non-African patients (46.4% vs. 29.1%, p <0.001). HDV viral load at baseline was significantly lower in responders than in non-responders.

CONCLUSION

Place of birth, HDV genotype and persistent viremia constitute the main determinants of liver involvement and response to treatment in chronic HDV-infected patients.

LAY SUMMARY

Chronic liver infection by hepatitis delta virus (HDV) is the most severe form of chronic viral hepatitis. Despite the fact that at least 15-20 million people are chronically infected by HDV worldwide, factors determining the severity of liver involvement are largely unknown. By investigating a large cohort of 1,112 HDV-infected patients followed-up in France, but coming from different areas of the world, we were able to determine that HDV genotype, place of birth (reflecting both viral and host-related factors) and persistent viremia constitute the main determinants of liver involvement and response to treatment.

Collapse

Affiliation(s)

Dominique Roulot AP-HP, Hôpital Avicenne, Unité d'hépatologie, Université Paris 13, Bobigny; Inserm U955, équipe 18, Université Paris-Est, Créteil.
Ségolène Brichler AP-HP, Hôpital Avicenne, Laboratoire de microbiologie clinique, Université Paris 13, Centre national de référence des hépatites B, C et Delta, Bobigny, Inserm U955, équipe 18, Université Paris-Est, Créteil
Richard Layese AP-HP, Hôpital Henri-Mondor, Unité de Recherche Clinique, Université Paris-Est, DHU A-TVB, IMRB- EA 7376 CEpiA (Clinical Epidemiology and Ageing Unit), Créteil
Zahia BenAbdesselam AP-HP, Hôpital Avicenne, Unité d'hépatologie et Centre de Recherche Clinique, Bobigny
Fabien Zoulim Hospices civils de Lyon, Hôpital Croix Rousse, Service d'hépatologie; Inserm U1052; Université de Lyon
Vincent Thibault CHU de Rennes, Inserm, EHESP, Irset-UMR S1085, Rennes
Caroline Scholtes Hospices civils de Lyon, Hôpital Croix Rousse, Département de virologie, Université de Lyon
Bruno Roche AP-HP, Hopital Paul Brousse, Service d'hépatologie, Villejuif
Corinne Castelnau AP-HP, Hopital Beaujon, Service d'hépatologie, Clichy
Thierry Poynard AP-HP, Groupe hospitalier Pitié-Salpêtriere, Service d'hépatologie, Sorbonne Université, Paris
Olivier Chazouillères AP-HP, Hopital Saint-Antoine, Service d'hépatologie et Centre de Recherche, Inserm, Sorbonne Université, Paris
Nathalie Ganne AP-HP, Hôpital Jean-Verdier, Service d'hépatologie, Bondy, Université Paris 13, Bobigny; Inserm U1162, Université Paris 5, Paris
Hélène Fontaine AP-HP, Hôpital Cochin, Service d'hépatologie, Paris
Jerome Gournay CHU de Nantes, Hopital Hôtel Dieu, Département d'hépatogastroentérologie, Nantes
Dominique Guyader CHU de Rennes, Service d'hépatologie, Rennes
Frédéric Le Gal AP-HP, Hôpital Avicenne, Laboratoire de microbiologie clinique, Université Paris 13, Centre national de référence des hépatites B, C et Delta, Bobigny, Inserm U955, équipe 18, Université Paris-Est, Créteil
Pierre Nahon AP-HP, Hôpital Jean-Verdier, Service d'hépatologie, Bondy, Université Paris 13, Bobigny; Inserm U1162, Université Paris 5, Paris
Françoise Roudot-Thoraval AP-HP, Hôpital Henri-Mondor, Unité de Recherche Clinique, Université Paris-Est, DHU A-TVB, IMRB- EA 7376 CEpiA (Clinical Epidemiology and Ageing Unit), Créteil; AP-HP, Hôpital Henri-Mondor, Service d'hépatologie, Créteil
Emmanuel Gordien AP-HP, Hôpital Avicenne, Laboratoire de microbiologie clinique, Université Paris 13, Centre national de référence des hépatites B, C et Delta, Bobigny, Inserm U955, équipe 18, Université Paris-Est, Créteil

Roland Landman
Christophe Hezode
Ghassan Riachi
Caroline Lascoux-Combe
Véronique Loustaud-Ratti
Isabelle Rosa
Philippe Mathurin
Eric Nguyen-Khac
Xavier Causse
Sylvie Naveau
François Habersetzer
Sophie Metivier
Hélène Labadie
Pierre Sellier
Julie Bottero
Victor de Ledinghen
Laurent Alric
Paul Calès
Cecile Goujard
Jean-François Cadranel
Dominique Salmon
Sophie Hillaire

Collapse

Wu S, Zhang Y, Tang Y, Yao T, Lv M, Tang Z, Zang G, Yu Y, Chen X. Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China. BMC Infect Dis 2020;20:565. [PMID: 32746807 PMCID: PMC7397625 DOI: 10.1186/s12879-020-05275-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Accepted: 07/20/2020] [Indexed: 12/18/2022] Open

Mammalian deltavirus without hepadnavirus coinfection in the neotropical rodent Proechimys semispinosus. Proc Natl Acad Sci U S A 2020;117:17977-17983. [PMID: 32651267 PMCID: PMC7395443 DOI: 10.1073/pnas.2006750117] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open

Lin GY, Wu YL, Wang CS, Ko CY, Chen CH, Chen PJ, Peng PH, Hsu CW. Performance of commercially available anti-HDV enzyme-linked immunosorbent assays in Taiwan. Virol J 2020;17:76. [PMID: 32546164 PMCID: PMC7298757 DOI: 10.1186/s12985-020-01355-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Accepted: 06/12/2020] [Indexed: 02/06/2023] Open

Abstract

Background

Hepatitis D virus (HDV) infection is a major global health issue around the world. There are approximately 15–20 million individuals infected with HDV worldwide. HDV infection usually causes increased mortality compared with infection with hepatitis B virus (HBV) alone. However, testing for the detection of HDV is not widely available in Taiwan. Therefore, the General Biologicals Corporation (GB) HDV Ab kit was developed for detecting anti-HDV antibodies.

Methods

A total of 913 serum and 462 EDTA-treated plasma samples were obtained from HBsAg-positive individuals in three hospitals in Taiwan from June 2014 to November 2017. We used three commercially available ELISA kits, DiaPro HDV Ab, DiaSorin ETI-AB-DELTAK-2 and GB HDV Ab, which were utilized strictly according to the instructions of the manufacturers.

Results

A comparative study of the results from the GB HDV Ab kit and the other commercial ELISA kits (DiaPro and DiaSorin) was performed to determine their efficacy for anti-HDV detection. The results indicated that the sensitivity of the GB HDV Ab kit for serum and EDTA samples was 100% compared to that of the DiaPro and DiaSorin kits, whereas the specificity for serum and EDTA samples was 99.3 and 98.1%, respectively. In addition, the overall agreement of the results of the GB HDV Ab kit for the serum and EDTA samples was 99.3 and 98.3%, respectively. It is worth noting that the performance of the GB HDV Ab kit was not affected by interference from triglyceride, bilirubin, hemoglobin, or human anti-mouse antibody. The limit of detection of the GB HDV Ab kit is approximately 100-fold lower than that of the other two commercial kits.

Conclusions

The GB HDV Ab kit, which presented equivalent sensitivity and specificity compared to both certified anti-HDV kits, would be a suitable kit for HDV diagnosis in Taiwan.

Collapse

Spaan M, Carey I, Bruce M, Shang D, Horner M, Dusheiko G, Agarwal K. Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1. J Hepatol 2020;72:1097-1104. [PMID: 31981726 DOI: 10.1016/j.jhep.2019.12.028] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Revised: 12/29/2019] [Accepted: 12/31/2019] [Indexed: 02/02/2023]

Abstract

BACKGROUND & AIMS

Coinfection with HDV causes rapid progression to liver cirrhosis and hepatic decompensation in patients with chronic hepatitis B. Factors that are associated with disease progression are poorly understood. In this study we aim to identify risk factors associated with disease progression and better characterise clinical differences and treatment response between HDV genotype 1 and 5.

METHODS

In this retrospective study, all patients under our care between 2005 and 2016 with HBV/HDV coinfection (HBsAg+, anti-HDV antibodies positive) were analysed. Patients were excluded if follow-up was less than 6 months, if they had HCV and/or HIV coinfection or an acute HDV infection. Demographic data, stage of liver disease, development of liver complications and treatment response were recorded.

RESULTS

One-hundred seven patients (mean age 36.0 years, 57% male) were followed for a median period of 4.4 years (range 0.6-28.1 years); 64% were of African origin and 17% were of European origin, with 28% of patients being cirrhotic at first visit; 43% patients had actively replicating HDV virus (anti-HDV-IgG+, anti-HDV-IgM+ or HDV RNA+) and 57% of patients were HDV exposed (anti-HDV-IgG+, HDV RNA-). Patients with actively replicating HDV more often developed liver complications than HDV-exposed patients (p = 0.002), but no differences in baseline characteristics were observed. Patients with HDV genotype 5 less often developed cirrhosis or hepatic decompensation compared to patients with HDV genotype 1. Twenty-four patients were treated with peg-IFN and post-treatment response was significantly better in patients infected with genotype 5 (10% GT1 vs. 64% GT5, p = 0.013).

CONCLUSION

Patients infected with HDV genotype 5 appear to have a better prognosis with fewer episodes of hepatic decompensation and better response to peg-IFN treatment than patients infected with HDV genotype 1.

LAY SUMMARY

Hepatitis delta is a virus that affects the liver. The virus is known to have different subtypes, called genotypes. With this research we discovered that hepatitis delta virus genotype 1 behaves differently than genotype 5 and causes faster development of liver disease. This is important for education of our patients and to determine how often we need to check our patients.

Collapse

Statin inhibits large hepatitis delta antigen-Smad3 -twist-mediated epithelial-to-mesenchymal transition and hepatitis D virus secretion. J Biomed Sci 2020;27:65. [PMID: 32434501 PMCID: PMC7240974 DOI: 10.1186/s12929-020-00659-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2020] [Accepted: 05/14/2020] [Indexed: 01/01/2023] Open

HDVdb: A Comprehensive Hepatitis D Virus Database. Viruses 2020;12:v12050538. [PMID: 32422927 PMCID: PMC7290977 DOI: 10.3390/v12050538] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 05/10/2020] [Accepted: 05/11/2020] [Indexed: 02/06/2023] Open

Snake Deltavirus Utilizes Envelope Proteins of Different Viruses To Generate Infectious Particles. mBio 2020;11:mBio.03250-19. [PMID: 32184255 PMCID: PMC7078484 DOI: 10.1128/mbio.03250-19] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open

Abstract

Satellite viruses, most commonly found in plants, rely on helper viruses to complete their replication cycle. The only known example of a human satellite virus is the hepatitis D virus (HDV), and it is generally thought to require hepatitis B virus (HBV) to form infectious particles. Until 2018, HDV was the sole representative of the genus Deltavirus and was thought to have evolved in humans, the only known HDV host. The subsequent identification of HDV-like agents in birds, snakes, fish, amphibians, and invertebrates indicated that the evolutionary history of deltaviruses is likely much longer than previously hypothesized. Interestingly, none of the HDV-like agents were found in coinfection with an HBV-like agent, suggesting that these viruses use different helper virus(es). Here we show, using snake deltavirus (SDeV), that HBV and hepadnaviruses represent only one example of helper viruses for deltaviruses. We cloned the SDeV genome into a mammalian expression plasmid, and by transfection could initiate SDeV replication in cultured snake and mammalian cell lines. By superinfecting persistently SDeV-infected cells with reptarenaviruses and hartmaniviruses, or by transfecting their surface proteins, we could induce production of infectious SDeV particles. Our findings indicate that deltaviruses can likely use a multitude of helper viruses or even viral glycoproteins to form infectious particles. This suggests that persistent infections, such as those caused by arenaviruses and orthohantaviruses used in this study, and recurrent infections would be beneficial for the spread of deltaviruses. It seems plausible that further human or animal disease associations with deltavirus infections will be identified in the future.IMPORTANCE Deltaviruses need a coinfecting enveloped virus to produce infectious particles necessary for transmission to a new host. Hepatitis D virus (HDV), the only known deltavirus until 2018, has been found only in humans, and its coinfection with hepatitis B virus (HBV) is linked with fulminant hepatitis. The recent discovery of deltaviruses without a coinfecting HBV-like agent in several different taxa suggested that deltaviruses could employ coinfection by other enveloped viruses to complete their life cycle. In this report, we show that snake deltavirus (SDeV) efficiently utilizes coinfecting reptarena- and hartmaniviruses to form infectious particles. Furthermore, we demonstrate that cells expressing the envelope proteins of arenaviruses and orthohantaviruses produce infectious SDeV particles. As the envelope proteins are responsible for binding and infecting new host cells, our findings indicate that deltaviruses are likely not restricted in their tissue tropism, implying that they could be linked to animal or human diseases other than hepatitis.

Collapse

Sharafi H, Rezaee-Zavareh MS, Miri SM, Alavian SM. Global Distribution of Hepatitis D Virus Genotypes: A Systematic Review. HEPATITIS MONTHLY 2020;20. [DOI: 10.5812/hepatmon.102268] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2023]

Aftab M, Naz S, Aftab B, Ali A, Rafique S, Fatima Z, Inamullah, Idrees M. Characterization of Hepatitis Delta Virus Among Pregnant Women of Pakistan. Viral Immunol 2019;32:335-340. [PMID: 31553269 DOI: 10.1089/vim.2019.0048] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open

Gilman C, Heller T, Koh C. Chronic hepatitis delta: A state-of-the-art review and new therapies. World J Gastroenterol 2019;25:4580-4597. [PMID: 31528088 PMCID: PMC6718034 DOI: 10.3748/wjg.v25.i32.4580] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Revised: 07/03/2019] [Accepted: 07/19/2019] [Indexed: 02/06/2023] Open

Coppola N, Alessio L, Onorato L, Sagnelli C, Sagnelli E, Pisaturo M. HDV infection in immigrant populations. J Med Virol 2019;91:2049-2058. [PMID: 31429940 DOI: 10.1002/jmv.25570] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Accepted: 08/10/2019] [Indexed: 12/16/2022]